Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Dermatological map could lead to new treatments
Fri January 22nd - A newly created skin cell map offers a “huge leap” in understanding of disease and could pave the way for potential drug treatments for painful skin diseases, British researchers say. More
Half a million doctors needed for cancer surgery
Fri January 22nd - The world will need half a million more doctors in the next 20 years, just to cope with growing demand for cancer surgery, according to a major new analysis. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Gene testing to boost male cancer treatment

Wednesday October 12th, 2011

Routine gene testing could help determine the best treatment for prostate cancer patients, researchers reported today.

Faults in the BRCA2 gene could mean the patient would benefit from targeted therapies such as PARP inhibitors. These drugs appear to be effective against several types of cancer linked to BRCA mutations.

Professor Ros Eeles from the Institute of Cancer Research, London, UK, and colleagues looked at the genes of almost 2,000 men with prostate cancer. They found that one per cent of patients below the age of 65 had a faulty BRCA2 gene.

Professor Eeles said: "Our study shows that men diagnosed with prostate cancer at a young age have a higher chance of carrying a faulty BRCA2 gene.

"With the arrival of PARP inhibiting drugs to target tumours with BRCA mutations, there may be benefits from routinely testing prostate cancer patients diagnosed before 65 for this gene fault.

"Prostate cancer patients with this gene fault also tend to have a poorer prognosis so we are also studying whether BRCA2 mutations are more common among patients with more aggressive disease. Ultimately, we hope to develop a full clinical picture of BRCA2-linked cancers, which will help us to work out the best way to treat these patients."

The research is published in the British Journal of Cancer. It was partly funded by Cancer Research UK.

Dr Lesley Walker, of Cancer Research UK, commented: "Once gene testing becomes faster and cheaper, this study suggests that a new range of treatments could potentially open up for some prostate cancer patients.

"It would be great if we could use PARP inhibitors to treat prostate cancer."

* A second study has found that taking vitamin E supplements can increase the risk of developing prostate cancer.

The report in the Journal of the American Medical Association came from a study of some 37,000 men in North America.

Researchers found a 17 per cent increase in rates of prostate cancer among men who took vitamin E in a study aimed at testing the theory it might reduce the risk.

BRCA2 is a moderate penetrance gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients. Kote-Jarai, Z. et al. The British Journal of Cancer, published online October 12 2011.

Journal of the American Medical Association October 12 2011;306[14]:1549-1556

Tags: Cancer | Diet & Food | Genetics | Menís Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page